Head and Neck Cancer News and Research

RSS

Head and Neck Cancer is cancer that arises in the head or neck region (in the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx [voice box]).

Updated data from Vical's Phase 2 trial of high-dose Allovectin-7 in metastatic melanoma patients

Vical Incorporated announced the publication in the June issue of Melanoma Research of updated data from the company's Phase 2 trial of high-dose (2 mg) Allovectin-7® in patients with metastatic melanoma. A separate article in the May issue of Expert Opinion on Biological Therapy reviewed results from the Phase 2 trial and previous clinical studies of Allovectin-7®.

12 May 2010

Genmab reports revenues of DKK 107M for first-quarter 2010

Genmab's revenues were DKK 107 million (USD 19 million) for the first quarter of 2010. In the same period of 2009, Genmab recognized revenues of DKK 250 million (USD 45 million).

12 May 2010

Advanced radiation techniques treat head and neck cancer, reduce swallowing complications

Researchers at the University of Michigan Comprehensive Cancer Center have applied advanced radiation techniques for head and neck cancer to avoid treating critical structures that affect swallowing and eating.

11 May 2010

Update on CEL-SCI's Phase III clinical trial of Multikine

CEL-SCI Corporation today provided an update on its planned Phase III clinical trial of its cancer immunotherapy drug candidate Multikine. The Company, together with its development partners Teva Pharmaceutical Industries and Orient Europharma, has already selected 40 of the planned 50 global medical centers where the Multikine Phase III study will be conducted.

6 May 2010

IRX Therapeutics and Japan's NCRC collaborate to evaluate peptide-based cancer vaccines

IRX Therapeutics, a developer of novel immunomodulators to treat cancer and viral diseases, today announced that it has established a strategic collaboration with Japan's National Cancer Research Center (NCRC) to evaluate next-generation peptide-based cancer vaccines. Clinical research will be conducted at NCRC. IRX Therapeutics will provide its proprietary IRX-2 immunomodulatory regimen, clinical trial design and technical support. This is the first collaboration of its kind between the NCRC and a U.S.-based biotechnology firm.

30 Apr 2010

Head- and neck-cancer patients who continue to smoke during radiation therapy have poorer overall survival

Smokers who don't quit before radiation therapy for throat, mouth and other head and neck cancers fair significantly worse than those who do, research from the UC Davis Cancer Center has found.

28 Apr 2010

Study suggests way to predict tumors most likely to respond to chemotherapy and radiation

Levels of a key type of immune cell are higher in head and neck cancer patients whose tumors are linked to the human papillomavirus, or HPV, according to researchers at the University of Michigan Comprehensive Cancer Center.

27 Apr 2010

Aspen Dental donates $2,300 to Oral Cancer Foundation for cancer detection and treatment

Aspen Dental announced today that the company will donate $2,300 to the Oral Cancer Foundation as part of its commitment to oral cancer detection and treatment. The amount represents a $5 donation for every Vizilite Plus screening conducted at Aspen Dental offices during Oral, Head, and Neck Cancer Awareness Week (April 12-18, 2010).

22 Apr 2010

Access Pharmaceuticals to present MuGard clinical data at 2010 MASCC conference

ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company specializing in products for cancer and supportive care, announced today that it will present data from the ongoing work involving its lead product, MuGard, and host an oral mucositis symposium at the MASCC conference being held in Vancouver, B.C. on June 24-26, 2010. MuGard is Access Pharma's FDA-approved product for the management of oral mucositis, a debilitating side effect of many anticancer treatments.

22 Apr 2010

Strativa Pharmaceuticals: Oravig buccal tablets receive FDA approval for OPC

Strativa Pharmaceuticals today announced that the U.S. Food and Drug Administration has approved Oravig (miconazole) buccal tablets for the treatment of oropharyngeal candidiasis, more commonly known as thrush, in adults and children age 16 and older.

17 Apr 2010

Men who live further from cities more likely to have chronic health problems and higher death rates, says report

According to a new report from the Australian Institute of Health and Welfare, rural men are more prone to succumb to diseases like diabetes, some cancers like of head, neck and lip, poisonings and chronic health problems compared to those living in major cities.

14 Apr 2010

Loyola University Medical Center to offer free screenings for oral, head and neck cancer

Oral, head and neck cancers — most of which are preventable — account for approximately 3 percent of all cancer cases in the United States, according to the American Cancer Society. In 2009, more than 35,000 Americans were diagnosed with these cancers and 7,600 died.

8 Apr 2010

Johns Hopkins Kimmel Cancer Center reviews top cancer stories

Surgeon Jeremy Richmon, M.D., at Johns Hopkins is using robotic assistance to cut away tumors of the tongue and tonsils. Conventional surgery leaves disfiguring neck and jaw scars, but the robotic procedure leaves no scar except for inside the mouth, and he says, patients retain good function of speech and swallowing.

5 Apr 2010

Detroit cancer center to conduct free oral, head and neck cancer screenings

On Friday, April 16, from 2 - 5 p.m., the Barbara Ann Karmanos Cancer Center in Detroit will be conducting free oral, head and neck cancer screenings in conjunction with National Oral Head and Neck Cancer Awareness Week (April 12 – 18.) Some of the symptoms of oral cancer go unnoticed. A simple 10-minute screening exam can determine if there are problems and can help diagnose this disease in its early stage.

3 Apr 2010

Identification and elimination of cancer stem cells

A new field of cancer research could explain why some cancers that appear to have been cured can rear their ugly head or spread to other organs.

3 Apr 2010

CTRC commences enrollment in Phase 2 trial of REOLYSIN combination for SCC lung cancer

A virus that destroys cancer cells but leaves normal cells unharmed may offer hope to those affected by squamous cell carcinoma of the lungs (SCC lung cancer), according to investigators from the Cancer Therapy & Research Center (CTRC) at the University of Texas Health Science Center at San Antonio. The CTRC has started patient enrollment in a US Phase 2 clinical trial using intravenous administration of REOLYSIN® in combination with carboplatin and paclitaxel in patients with SCC lung cancer.

3 Apr 2010

Rosetta Genomics reports revenues of $150,000 for full-year 2009

Rosetta Genomics, Ltd., a leading developer of microRNA-based molecular diagnostics, today reported that on March 26, 2010 the Company filed its Form 20-F with the U.S. Securities and Exchange Committee, which contains financial results for the three and 12 months ended December 31, 2009.

31 Mar 2010

Prevalence of head and neck cancer linked to human papillomavirus

Rates of oropharangeal cancer have increased by around 50 per cent in the last 20 years, according to a report in the British Medical Journal.

31 Mar 2010

CTRC initiates patient enrolment in U.S. Phase 2 clinical trial of REOLYSIN

Oncolytics Biotech Inc. announced today that the Cancer Therapy & Research Center at the University of Texas Health Science Center has started patient enrolment in a U.S. Phase 2 clinical trial using intravenous administration of REOLYSIN(R) in combination with carboplatin and paclitaxel in patients with squamous cell carcinoma of the lungs.

30 Mar 2010

Inflamed tissues linked to increased production of protein involved in pain signaling

Using a novel animal model to study craniofacial pain, researchers at Oregon Health & Science University's School of Dentistry have discovered that when tissues are inflamed, the nerve cells carrying pain information from the head to the brain produce in large quantities a protein involved in pain signaling.

26 Mar 2010

Head and Neck Cancer News and Research

Updated data from Vical's Phase 2 trial of high-dose Allovectin-7 in metastatic melanoma patients

Genmab reports revenues of DKK 107M for first-quarter 2010

Advanced radiation techniques treat head and neck cancer, reduce swallowing complications

Update on CEL-SCI's Phase III clinical trial of Multikine

IRX Therapeutics and Japan's NCRC collaborate to evaluate peptide-based cancer vaccines

Head- and neck-cancer patients who continue to smoke during radiation therapy have poorer overall survival

Study suggests way to predict tumors most likely to respond to chemotherapy and radiation

Aspen Dental donates $2,300 to Oral Cancer Foundation for cancer detection and treatment

Access Pharmaceuticals to present MuGard clinical data at 2010 MASCC conference

Strativa Pharmaceuticals: Oravig buccal tablets receive FDA approval for OPC

Men who live further from cities more likely to have chronic health problems and higher death rates, says report

Loyola University Medical Center to offer free screenings for oral, head and neck cancer

Johns Hopkins Kimmel Cancer Center reviews top cancer stories

Detroit cancer center to conduct free oral, head and neck cancer screenings

Identification and elimination of cancer stem cells

CTRC commences enrollment in Phase 2 trial of REOLYSIN combination for SCC lung cancer

Rosetta Genomics reports revenues of $150,000 for full-year 2009

Prevalence of head and neck cancer linked to human papillomavirus

CTRC initiates patient enrolment in U.S. Phase 2 clinical trial of REOLYSIN

Inflamed tissues linked to increased production of protein involved in pain signaling

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News